---
title: "LB Pharmaceuticals Launches Phase 2 Trial of LB-102 for Bipolar Depression"
description: "LB Pharmaceuticals Inc. has launched a Phase 2 clinical trial, ILLUMINATE-1, to assess the efficacy and safety of LB-102 for bipolar depression. The trial will involve around 320 patients across 30 U."
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/273704681.md"
published_at: "2026-01-26T13:02:09.000Z"
---

# LB Pharmaceuticals Launches Phase 2 Trial of LB-102 for Bipolar Depression

> LB Pharmaceuticals Inc. has launched a Phase 2 clinical trial, ILLUMINATE-1, to assess the efficacy and safety of LB-102 for bipolar depression. The trial will involve around 320 patients across 30 U.S. sites, with participants receiving either 25 mg or 50 mg doses of LB-102 or placebo over six weeks. The primary endpoint is the MADRS-10 at week six, with topline results expected in Q1 2028. This announcement is for informational purposes only and not financial advice.

LB Pharmaceuticals Inc. has announced the initiation of a Phase 2 clinical trial, ILLUMINATE-1, to evaluate the efficacy and safety of LB-102 in patients with bipolar depression. LB-102 is a novel, once-daily oral small molecule and a selective antagonist of D2, D3, and 5HT7 receptors. The randomized, double-blind, placebo-controlled trial will enroll approximately 320 patients with bipolar 1 depression across 30 sites in the U.S., with participants receiving either 25 mg or 50 mg doses of LB-102 or placebo over six weeks. The primary endpoint is the Montgomery-Åsberg Depression Rating Scale (MADRS)-10 at week six. Secondary endpoints include MADRS-6, CGI-BP, cognition, anhedonia, safety, and tolerability. Topline results from the trial are expected in the first quarter of 2028. Results have not yet been presented. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LB Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9631810) on January 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [LBRX.US - LB Pharmaceuticals](https://longbridge.com/en/quote/LBRX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| LB Pharmaceuticals Raises $100 Million in Private Placement with Shares and Pre-Funded Warrants Issued | LB Pharmaceuticals Inc. has raised $100 million through a private placement, issuing pre-funded warrants for 1,417,107 s | [Link](https://longbridge.com/en/news/274977918.md) |
| Medexus Pharmaceuticals reports Q3 results | Medexus Pharmaceuticals reports Q3 results | [Link](https://longbridge.com/en/news/275670725.md) |
| Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ \| CTOR Stock News | Citius Pharmaceuticals, Inc. reported $3.9 million in revenue from the launch of LYMPHIR™ in December 2025, marking its  | [Link](https://longbridge.com/en/news/275904512.md) |
| Zentalis Pharmaceuticals PAO and PFO Vincent Vultaggio Reports Disposal of Common Shares | Vincent Vultaggio, PAO and PFO of Zentalis Pharmaceuticals Inc., reported the disposal of common shares of the company.  | [Link](https://longbridge.com/en/news/275538961.md) |
| BioRestorative concludes Phase II BRTX-100 trial enrolment for cLDD | BioRestorative Therapies has completed patient enrolment in its Phase II trial for BRTX-100, aimed at treating chronic l | [Link](https://longbridge.com/en/news/275588198.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.